Exploring the Impact of CDK 4/6 Inhibitors Through Case-Based Panel Discussion

Speciality: Rheumatology


Speaker:

Dr. Narendra Agarwal | Sr. Consultant, Hematology, RGCIRC

Dr. Rayaz Ahmed | Sr. Consultant, Hematology, RGCIRC

Dr. Narender Tejwani | Consultant Hematopathology, RGCIRC

Description:

A warm welcome to all the medical professionals in this case-based panel discussion on the role of CDK 4/6 inhibitors in clinical practice. 

Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of anticancer medications. It is also helpful in reducing or eliminating endocrine resistance when used in combination with endocrine therapy. It can be used for the treatment of hormone receptor–positive (HR+) breast cancer.

The CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib are observed to enhance the change in the treatment paradigm for patients with HR+/HER2− advanced breast cancer. Moreover, these drugs have demonstrated a meaningful improvement in PFS when used for first- or later-line therapy.

Therefore, listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study opens up possibility of bespoke prostate cancer treatment

2.

Why Encouragement May Not Improve Motivation in Depression

3.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

4.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

5.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot